Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Johnson and Johnson
Moodys
McKesson
Medtronic

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Trafermin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Trafermin: Sponsors, patents, clinical trial progress

Trafermin is an investigational drug.

There have been 6 clinical trials for Trafermin. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2010.

The most common disease conditions in clinical trials are Periodontitis, Ulcer, and Foot Ulcer. The leading clinical trial sponsors are Kaken Pharmaceutical, Olympus Biotech Corporation, and [disabled in preview].

There are four US patents protecting this investigational drug and twenty-six international patents.

Recent Clinical Trials for Trafermin
TitleSponsorPhase
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North StudyOlympus Biotech CorporationPhase 3
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South StudyOlympus Biotech CorporationPhase 3
A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)Kaken PharmaceuticalPhase 3

See all Trafermin clinical trials

Clinical Trial Summary for Trafermin

Top disease conditions for Trafermin
Top clinical trial sponsors for Trafermin

See all Trafermin clinical trials

US Patents for Trafermin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Trafermin   Start Trial Agent for regenerating tympanic membrane or external auditory canal NOBELPHARMA CO., LTD. (Tokyo, JP)   Start Trial
Trafermin   Start Trial Polysaccharides for pulmonary delivery of active agents Momenta Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Trafermin   Start Trial Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients Torrent Pharmaceuticals Limited (Ahmedabad, IN)   Start Trial
Trafermin   Start Trial Modified release composition for highly soluble drugs Torrent Pharmaceuticals Limited (Ahmedabad, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Trafermin

Drugname Country Document Number Estimated Expiration Related US Patent
Trafermin Australia 2009263249 2028-06-26   Start Trial
Trafermin Brazil PI0915387 2028-06-26   Start Trial
Trafermin Canada 2729093 2028-06-26   Start Trial
Trafermin China 102131478 2028-06-26   Start Trial
Trafermin China 105381506 2028-06-26   Start Trial
Trafermin European Patent Office 2353547 2028-06-26   Start Trial
Trafermin Spain 2671068 2028-06-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Medtronic
Colorcon
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.